These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17703641)

  • 21. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare use and voluntary health insurance after retirement in Thailand.
    Kananurak P
    Appl Health Econ Health Policy; 2014 Jun; 12(3):299-313. PubMed ID: 24500818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.
    Śliwczyński A; Brzozowska M; Jacyna A; Iltchev P; Iwańczuk T; Wierzba W; Marczak M; Orlewska K; Szymański P; Orlewska E
    PLoS One; 2017; 12(6):e0178764. PubMed ID: 28582404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying factors that affect patients' willingness to pay for inhaled insulin.
    Pinto SL; Holiday-Goodman M; Black CD; Lesch D
    Res Social Adm Pharm; 2009 Sep; 5(3):253-61. PubMed ID: 19733826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budget impact analysis of insulin therapies and associated delivery systems.
    Lee LJ; Smolen LJ; Klein TM; Foster SA; Whiteman D; Jorgenson JA; Hultgren S
    Am J Health Syst Pharm; 2012 Jun; 69(11):958-65. PubMed ID: 22610028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.
    Hung A; Mullins CD; Slejko JF; Haines ST; Shaya F; Lugo A
    J Manag Care Spec Pharm; 2019 Mar; 25(3):342-349. PubMed ID: 30816818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes costs rise, but so does adherence.
    Manag Care; 2005 Apr; 14(4):54. PubMed ID: 15898213
    [No Abstract]   [Full Text] [Related]  

  • 29. The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach.
    Marcellusi A; Viti R; Mecozzi A; Mennini FS
    Eur J Health Econ; 2016 Mar; 17(2):139-47. PubMed ID: 25427540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Savings needed to fund health insurance and health care expenses in retirement.
    Fronstin P
    EBRI Issue Brief; 2006 Jul; (295):1, 4-31. PubMed ID: 16910163
    [No Abstract]   [Full Text] [Related]  

  • 31. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
    Eby EL; Boye KS; Lage MJ
    J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health insurance, cost expectations, and adverse job turnover.
    Ellis RP; Albert Ma CT
    Health Econ; 2011 Jan; 20(1):27-44. PubMed ID: 20104505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health care spending fell sharply in first half of 2003; will premiums follow?
    Hosp Health Netw; 2004 Feb; 78(2):76-7. PubMed ID: 14999881
    [No Abstract]   [Full Text] [Related]  

  • 34. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
    McLeod L; Bereza BG; Shim M; Grootendorst P
    Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.
    Lipska KJ; Ross JS; Van Houten HK; Beran D; Yudkin JS; Shah ND
    JAMA; 2014 Jun; 311(22):2331-3. PubMed ID: 24915266
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjusting employer group capitation premiums by Community Rating by class factors.
    Cave DG; Schweitzer SO; Lachenbruch PA
    Med Care; 1989 Sep; 27(9):887-99. PubMed ID: 2505003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
    Narang AK; Nicholas LH
    JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A modeling framework for optimal long-term care insurance purchase decisions in retirement planning.
    Gupta A; Li L
    Health Care Manag Sci; 2004 May; 7(2):105-17. PubMed ID: 15152975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Annual Total Medical Expenditures Associated with Hypertension by Diabetes Status in U.S. Adults.
    Wang G; Zhou X; Zhuo X; Zhang P
    Am J Prev Med; 2017 Dec; 53(6S2):S182-S189. PubMed ID: 29153119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.